Ankyra is developing a platform to improve both the safety and efficacy of cytokine immunotherapies for cancer. Systemic dosing of these powerful immune stimulants is limited by broad immune activation and toxicity. We have developed methods to localize cytokines specifically and persistently when injected into tumor tissue, creating intense hot spots of inflammation that awaken an anti-tumor immune response. We are developing this approach for the treatment of solid tumors.

Founders

Tillman Gerngross, Ph.D.

Tillman Gerngross, Ph.D.

Co-Founder and Chairman of the Board

Karl Dane Wittrup, Ph.D.

Karl Dane Wittrup, Ph.D.

Co-founder

Darrell Irvine, Ph.D.

Darrell Irvine, Ph.D.

Co-founder

Team

Joshua Allen

Joshua Allen

Staff Accountant

Farzian Aminuddin, MBA

Farzian Aminuddin, MBA

Sr. Director, Business Development

Sailaja Battula, Ph.D.

Sailaja Battula, Ph.D.

Vice President, Research and Development

Margretta Beaty

Margretta Beaty

Clinical Trial Manager

Dianne Brennick

Dianne Brennick

Associate Director, Human Resources

Joseph Elassal M.D., MBA

Joseph Elassal M.D., MBA

Chief Medical Officer

Stephen Gorgol

Stephen Gorgol

Chief Financial Officer

Gail Iodice, BSN RN

Gail Iodice, BSN RN

Vice President, Clinical Development

Kanika Jain, Ph.D.

Kanika Jain, Ph.D.

Scientist I

Howard L. Kaufman, M.D., FACS

Howard L. Kaufman, M.D., FACS

President and Chief Executive Officer

Cheryl K. Kent, MA

Cheryl K. Kent, MA

Senior Director, Clinical Operations

Donna Kiely

Donna Kiely

Vice President, Quality Assurance

Lynn Nicole

Lynn Nicole

Vice President, Regulatory Affairs

Dayna Resi

Dayna Resi

Senior Manager, Quality Assurance

Robert Tighe

Robert Tighe

Chief Scientific Officer

Lance Weed

Lance Weed

Vice President, Process and Manufacturing Sciences

Gregory Zarbis-Papastoitsis, Ph.D.

Gregory Zarbis-Papastoitsis, Ph.D.

Chief Process and Manufacturing Officer

Board of Directors

Tillman Gerngross, Ph.D.
Co-Founder of Adimab LLC
Terry McGuire
Partner, Polaris Partners
Ajay Royan
Partner, Mithril Capital
Phil Ferneau
Managing Partner, Borealis Ventures
Howard L. Kaufman, M.D., FACS
President and CEO, Ankyra Therapeutics
Julia G. Butchko, Ph.D
Chief Development Officer, Immunovant
Tara Withington
Vice President, Executive Director, Inc.

Scientific Advisory Board

Dr. Genevieve Boland, M.D, Ph.D.

Dr. Genevieve Boland, M.D, Ph.D.

Harvard Medical School, Massachusetts General Hospital

Dr. James L. Gulley, M.D., Ph.D.

Dr. James L. Gulley, M.D., Ph.D.

National Cancer Institute

Dr. John M. Kirkwood, M.D.

Dr. John M. Kirkwood, M.D.

University of Pittsburgh, UPMC Hillman Cancer Center

Dr. James J. Mulé, M.D.

Dr. James J. Mulé, M.D.

Moffitt Cancer Center

Dr. Jeffrey Schlom, Ph.D

Dr. Jeffrey Schlom, Ph.D

National Cancer Institute

Stefani Spranger, Ph.D.

Stefani Spranger, Ph.D.

Koch Institute for Integrative Cancer Research at MIT

Science

Scientific Publications

Posters and Presentations

Pipeline

1

Clinical Trials

Human Cancer Trials

A Phase 1, Open-Label, Dose Escalation Study of the Safety and Tolerability of ANK-101 in Advanced Cutaneous, Subcutaneous, Soft Tissue or Nodal Tumors
ClinicalTrials.gov Identifier: NCT06171750

For more information about our clinical trial, please contact us at info@ankyratx.com

Canine Trial

Evaluation of intratumoral alum-tethered canine interleukin-12 (cANK-101) in dogs with measurable oral malignant melanoma

check this out online pharmacy! Click to check prices now!

For information about enrolling a patient in the Ankyra trial at Illinois, please contact:
Rebecca Kamerer, CVT, Clinical Trials Coordinator:
rmoss81@illinois.edu, 217-300-6453

Culture

Our Commitment to Diversity and Inclusion

Ankyra Therapeutics strives to maintain an environment of strong employee engagement, which means that all employees must feel included and valued. We have sought to build and maintain a culture where inclusiveness and diversity is a reflex, and not a corporate initiative.

We have a deep sense of pride, passion, and belonging that transcends any individual position, business unit, language, or country; and we are unified in our shared commitment to excellence, innovation, and social responsibility. We understand that our success will be enhanced by including a diverse perspective which fosters different ideas, thoughts, and experiences to create a more creative work environment and to deliver better results.

Values

Scientific Integrity we value scientific rigor and honesty with a commitment to remain accountable, trustworthy and data-driven at all times.

Respect – we have developed a culture of respect to allow all people and perspectives to be communicated in an honest and open forum. We believe that respect for each other also leads to respect and improved communication with our key stakeholders, including investors, collaborators, consultants and patients. We also support an inclusive and diverse employee participation experience.

Innovation – we place a high emphasis on ‘out-of-the-box’ thinking and encourage new ideas and creative solutions to current challenges in drug development.

Teamwork – our culture is built around collaboration and teamwork as an important strategy for rapidly advancing scientific breakthroughs and clinical translation. We operate in a highly transparent, balanced and collegial working environment.

Passion –
we have brought together a diverse and highly skilled group of professionals who share a passion for improving the lives of patients with cancer.

Mission

The mission of Ankyra Therapeutics is to optimize the impact of anchored immunotherapy to improve the lives of patients with cancer.

Vision

Our vision is to be a leading authority in the delivery of intratumoral immunotherapy for patients with cancer.

Expanded Access Program

Ankyra Therapeutics is committed to providing patients with full transparency to our products and policies. Our current policy does not permit expanded access to any drug products since there is no clinical and/or safety data available. We will reconsider our expanded access policy for individual drugs once preliminary safety data is available for full analysis from planned Phase I clinical trials.

Please leave any messages at our patient access email at info@ankyratx.com

245 Main Street • 2nd Floor Cambridge, MA 02142
info@ankyratx.com